It is Poised to be a Bull Market for Bluebird bio Inc (BLUE)

With 3.07 million shares changed hands, the volume of the stock remained lighter than its average volume of 9.86 million shares. The 52-week range on BLUE shows that it touched its highest point at $5.53 and its lowest point at $0.88 during that stretch. It currently has a 1-year price target of $4.16. Beta for the stock currently stands at 0.76.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BLUE was down-trending over the past week, with a drop of -9.49%, but this was down by -10.79% over a month. Three-month performance dropped to -12.06% while six-month performance fell -58.94%. The stock lost -61.96% in the past year, while it has lost -10.14% so far this year. A look at the trailing 12-month EPS for BLUE yields -0.74 with Next year EPS estimates of -0.90. For the next quarter, that number is -0.45. This implies an EPS growth rate of 10.66% for this year and 45.82% for next year. EPS is expected to grow by 45.80% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 15.14%.

Float and Shares Shorts:

At present, 192.74 million BLUE shares are outstanding with a float of 189.83 million shares on hand for trading. On Mar 15, 2024, short shares totaled 34.04 million, which was 17.66% higher than short shares on Feb 15, 2024. In addition to BLUE as the firm’s bluebird bio, Inc., FBGRX serves as its Fidelity Blue Chip Growth Fund.

Institutional Ownership:

Through their ownership of 70.61% of BLUE’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BLUE since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, BLUE has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and BLUE currently yields $0.00. In the past year, BLUE’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, BLUE has a current buyback yield of $––. This was $–– for the TTM, and it was $–– for the past five years.